NASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis $0.57 +0.00 (+0.62%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$0.58 +0.01 (+1.23%) As of 08/22/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Femasys Stock (NASDAQ:FEMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Femasys alerts:Sign Up Key Stats Today's Range$0.55▼$0.6050-Day Range$0.57▼$0.9852-Week Range$0.55▼$1.80Volume1.04 million shsAverage Volume329,193 shsMarket Capitalization$18.60 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingBuy Company Overview Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia. Read More Femasys Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreFEMY MarketRank™: Femasys scored higher than 65% of companies evaluated by MarketBeat, and ranked 364th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingFemasys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFemasys has only been the subject of 1 research reports in the past 90 days.Read more about Femasys' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Femasys are expected to grow in the coming year, from ($0.86) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 11.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Femasys' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.41% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently increased by 150.31%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.41% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Femasys has recently increased by 150.31%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News Sentiment0.99 News SentimentFemasys has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Femasys this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for FEMY on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows4 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders11.54% of the stock of Femasys is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Femasys' insider trading history. Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Email Address FEMY Stock News HeadlinesFemasys Inc.: Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth ControlAugust 20 at 7:15 PM | finanznachrichten.deFemasys files to sell 11.43M shares of common stockAugust 20 at 7:15 PM | msn.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 23 at 2:00 AM | Weiss Ratings (Ad)Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth ControlAugust 20 at 7:15 PM | finance.yahoo.comFemasys Gains UK Approval for FemBloc Birth ControlAugust 20 at 9:51 AM | tipranks.comFemasys Inc. Advances European Commercialization of FemBloc Permanent Birth Control Following UK Regulatory ApprovalAugust 20 at 9:31 AM | quiverquant.comQHC Wainwright Analysts Raise Earnings Estimates for FemasysAugust 16, 2025 | americanbankingnews.comHC Wainwright Lowers Femasys (NASDAQ:FEMY) Price Target to $8.00August 13, 2025 | americanbankingnews.comSee More Headlines FEMY Stock Analysis - Frequently Asked Questions How have FEMY shares performed this year? Femasys' stock was trading at $1.10 at the beginning of the year. Since then, FEMY shares have decreased by 48.1% and is now trading at $0.5710. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) issued its quarterly earnings results on Friday, August, 8th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.80 million. Femasys had a negative net margin of 1,113.72% and a negative trailing twelve-month return on equity of 713.74%. When did Femasys IPO? Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO. Who are Femasys' major shareholders? Top institutional investors of Femasys include Clear Creek Financial Management LLC (0.87%) and Jane Street Group LLC (0.26%). View institutional ownership trends. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Femasys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE). Company Calendar Last Earnings8/08/2025Today8/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEMY CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Femasys$7.33 High Price Target$8.00 Low Price Target$6.00 Potential Upside/Downside+1,184.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.86) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.82 million Net Margins-1,113.72% Pretax Margin-1,113.30% Return on Equity-713.74% Return on Assets-152.60% Debt Debt-to-Equity Ratio0.03 Current Ratio0.89 Quick Ratio0.41 Sales & Book Value Annual Sales$1.63 million Price / Sales11.41 Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book11.42Miscellaneous Outstanding Shares32,580,000Free Float28,816,000Market Cap$18.60 million OptionableNot Optionable Beta-2.58 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NASDAQ:FEMY) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.